BioCardia (BCDA) Net Equity Issued and Repurchased (2020 - 2026)

BioCardia (BCDA) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $5.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 199.94% year-over-year to $5.1 million in Q2 2026; TTM through Jun 2026 was $12.1 million, a 521.38% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, down 17.65% from the prior year.
• Net Equity Issued and Repurchased was $5.1 million for Q2 2026 at BioCardia, up from $225000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $6.8 million in Q3 2025 and troughed at $39000.0 in Q4 2024.
• A 5-year average of $1.6 million and a median of $1.3 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased soared 151800.0% in 2022 and slumped 97.1% in 2024, its largest moves.
• Over 5 years, Net Equity Issued and Repurchased stood at $3.9 million in 2022, then slumped by 65.33% to $1.3 million in 2023, then tumbled by 97.1% to $39000.0 in 2024, then surged by 17292.31% to $6.8 million in 2025, then declined by 25.05% to $5.1 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $5.1 million (Q2 2026), $225000.0 (Q1 2026), and $6.8 million (Q3 2025), per Business Quant data.